tbuckley/cabot-search huggingface dataset:
1158MO Metabolomic profile of advanced neuroendocrine cancer patients
Authors: B. Soldevilla, A. Lens-Pardo, A. Lopez-Lopez, C. Carretero-Puche, A. La Salvia, M.C. Riesco-Martinez, P. Espinosa-Olarte, Á. López-Gonzálvez, C. Barbas, R. Garcia-Carbonero
Journal: Annals of Oncology (2020)
1334P Real word experience with first-line immunotherapy in advanced non-small cell lung cancer patients in a Danish nationwide cohort
Authors: M. Mouritzen, B. Bjoernhart, M. Poehl, M. Ladekarl, C. Vesteghem, M. Boegsted, A.W. Moelby Nielsen, P. Meldgaard, K.H. Hansen, J.W.W. Larsen, C. Kristiansen, K. Wedervang, A-C. Bareid-Oestby, M.S. Frank, G. Persson, E.B. Kristensen, P.H. Homann, A. Carus
Journal: Annals of Oncology (2020)
829P Regorafenib (R) or tamoxifen (T) for platinum-sensitive recurrent ovarian cancer (PSROC) with rising CA125 and no evidence of clinical or radiological disease progression: A GINECO randomized phase II trial
Authors: O. Tredan, M. Provansal Gross, C. Abdeddaim, S. Chabaud, A. Anota, I. Treilleux, D. Pissaloux, A.M. Savoye, A-C. Hardy Bessard, E. Kalbacher, A. Floquet, L. Venat-Bouvet, A. Lortholary, O. Pop, J-S. Frenel, M. Cancel, R. Largillier, C. Louvet, F. Brocard, I.L. Ray-Coquard
Journal: Annals of Oncology (2020)
834P A phase II study of gemcitabine, cisplatin, and bevacizumab for first recurrent and refractory ovarian clear-cell carcinoma (KCOG-G1601 trial)
Authors: K. Ito, M. Nakagawa, K. Hori, L. Tashima, M. Goto, S. Yanagida, J. Suzuki, R. Kaya, A. Kawabata, J. Park, H. Nasu, S. Nishio, E. Kondo, M. Kaneda, H. Tsubamoto, A. Arakawa, T. Nagasawa, K. Yamada
Journal: Annals of Oncology (2020)
302P Utility of lymphocyte-monocyte ratio (LMr) for predicting progression free survival (PFS) in patients with HR+/HER2- metastatic breast cancer (MBC) treated with palbocilcib + fulvestrant as first-line therapy
Authors: L. Raimondi, M. Pietranera, L. Rossi, A. Di Rocco, E. Gozzi, G. Cimino, G.P. Spinelli
Journal: Annals of Oncology (2020)
188P Breast cancer risk factors in Iran: A systematic review & meta-analysis
Authors: A. Shamshirian, K. Heydari, Z. Shams, A.R. Aref, D. Shamshirian, O.R. Tamtaji, Z. Asemi, H. Mirzaei, N. Mohammadi, B. Zibaee, K. Karimifar, B. Zarandi, A. Hedayatizadeh-Omran, R. Alizadeh-Navaei
Journal: Annals of Oncology (2020)
Epigenomics and transcriptomics of systemic sclerosis CD4+ T cells reveal long-range dysregulation of key inflammatory pathways mediated by disease-associated susceptibility loci
Authors: Tianlu Li, Lourdes Ortiz-Fernández, Eduardo Andrés-León, Laura Ciudad, Biola M. Javierre, Elena López-Isac, Alfredo Guillén-Del-Castillo, Carmen Pilar Simeón-Aznar, Esteban Ballestar, Javier Martin
Journal: Genome Medicine (2020)

Systemic sclerosis (SSc) is a genetically complex autoimmune disease mediated by the interplay between genetic and epigenetic factors in a multitude of immune cells, with CD4+ T lymphocytes as one of the principle drivers of pathogenesis.DNA samples exacted from CD4+ T cells of 48 SSc patients and 16 healthy controls were hybridized on MethylationEPIC BeadChip array. In parallel, gene expression was interrogated by hybridizing total RNA on Clariom™ S array. Downstream bioinformatics analyses were performed to identify correlating differentially methylated CpG positions (DMPs) and differentially expressed genes (DEGs), which were then confirmed utilizing previously published promoter capture Hi-C (PCHi-C) data.We identified 9112 and 3929 DMPs and DEGs, respectively. These DMPs and DEGs are enriched in functional categories related to inflammation and T cell biology. Furthermore, correlation analysis identified 17,500 possible DMP-DEG interaction pairs within a window of 5 Mb, and utilizing PCHi-C data, we observed that 212 CD4+ T cell-specific pairs of DMP-DEG also formed part of three-dimensional promoter-enhancer networks, potentially involving CTCF. Finally, combining PCHi-C data with SSc GWAS data, we identified four important SSc-associated susceptibility loci, TNIP1 (rs3792783), GSDMB (rs9303277), IL12RB1 (rs2305743), and CSK (rs1378942), that could potentially interact with DMP-DEG pairs cg17239269-ANXA6, cg19458020-CCR7, cg10808810-JUND, and cg11062629-ULK3, respectively.Our study unveils a potential link between genetic, epigenetic, and transcriptional deregulation in CD4+ T cells of SSc patients, providing a novel integrated view of molecular components driving SSc pathogenesis.
553P Activity of trastuzumab and pertuzumab (HP) in patients with non-breast/gastroesophgeal HER2-amplified tumours: Results of the NCI-MATCH trial (EAY131) subprotocol J
Authors: R.M. Connolly, V. Wang, D.M. Hyman, P. Grivas, E. Mitchell, J. Wright, E. Sharon, R.J. Gray, S. Li, L. McShane, L. Rubinstein, D.R. Patton, P.M. Williams, S. Hamilton, B. Conley, C.L. Arteaga, L. Harris, P.J. O'Dwyer, A. Chen, K.T. Flaherty
Journal: Annals of Oncology (2020)
Gestational age and the risk of autism spectrum disorder in Sweden, Finland, and Norway: A cohort study
Authors: Martina Persson, Signe Opdahl, Kari Risnes, Raz Gross, Eero Kajantie, Abraham Reichenberg, Mika Gissler, Sven Sandin
Journal: PLoS Medicine (2020)

Introduction The complex etiology of autism spectrum disorder (ASD) is still unresolved. Preterm birth (<37 weeks of gestation) and its complications are the leading cause of death of babies in the world, and those who survive often have long-term health problems. Length of gestation, including preterm birth, has been linked to ASD risk, but robust estimates for the whole range of gestational ages (GAs) are lacking. The primary objective of this study was to provide a detailed and robust description of ASD risk across the entire range of GAs while adjusting for sex and size for GA. Methods and findings Our study had a multinational cohort design, using population-based data from medical registries in three Nordic countries: Sweden, Finland, and Norway. GA was estimated in whole weeks based on ultrasound. Children were prospectively followed from birth for clinical diagnosis of ASD. Relative risk (RR) of ASD was estimated using log-binomial regression. Analyses were also stratified by sex and by size for GA. The study included 3,526,174 singletons born 1995 to 2015, including 50,816 (1.44%) individuals with ASD. In the whole cohort, 165,845 (4.7%) were born preterm. RR of ASD increased by GA, from 40 to 24 weeks and from 40 to 44 weeks of gestation. The RR of ASD in children born in weeks 22–31, 32–36, and 43–44 compared to weeks 37–42 were estimated at 2.31 (95% confidence interval [CI] 2.15–2.48; 1.67% vs 0.83%; p-value < 0.001), 1.35 (95% CI 1.30–1.40; 1.08% vs 0.83%; p-value < 0.001), and 1.37 (95% CI 1.21–1.54; 1.74% vs 0.83%; p-value < 0.001), respectively. The main limitation of this study is the lack of data on potential causes of pre- or postterm birth. Also, the possibility of residual confounding should be considered. Conclusion In the current study, we observed that the RR of ASD increased weekly as the date of delivery diverged from 40 weeks, both pre- and postterm, independently of sex and size for GA. Given the unknown etiology of ASD and the lifelong consequences of the disorder, identifying groups of increased risk associated with a potentially modifiable risk factor is important. Author summary
1659P AI-based grading approach identifies FNCLCC grade 3 soft tissue sarcomas
Authors: L.O. Schwen, J. Nitsch, S. Bauer, S. Bertram, M. Goetz, R. Hamacher, J. Hardes, A. Homeyer, D. Schacherer, A. Streitbürger, H. Höfener, H-U. Schildhaus
Journal: Annals of Oncology (2020)
577P Updated analysis of phase I dose-escalation and dose cohort expansion studies of senaparib (IMP4297) in Chinese patients with advanced solid tumours
Authors: B. Xu, C. Junning, H. Guo, P. Zhang, S. Yang, Y. Zhou, R. Zhang, J. Dongmei, W. Shen, S. Zhang, S. Cai, Y.E. Tian, C-Y. Hsieh, C. Xu, N. Ma, Y. Chen, S. Yang, S. Zhang
Journal: Annals of Oncology (2020)
LBA82 Influenza-like illness and SARS-Cov-2 in the multicenter, prospective, observational INVIDIa-2 study (INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: A transversal challenge): A FICOG study
Authors: M. Bersanelli, D. Giannarelli, E. Verzoni, S. Buti, U. De Giorgi, A. Clemente, M. Filetti, M. Di Napoli, L. Calvetti, P. Ermacora, A.M. Catino, G. Guaitoli, P. Bonomo, F. Mazzoni, A. Veccia, F. Grosso, M. Maruzzo, E. Rossi, F. Grossi, G. Procopio
Journal: Annals of Oncology (2020)
1304P Brigatinib (BRG) vs crizotinib (CRZ) in Asian vs non-Asian patients (pts): Update from ALTA-1L
Authors: M-J. Ahn, H.R. Kim, J.C-H. Yang, J-Y. Han, J.Y-C. Li, M.J. Hochmair, G-C. Chang, A. Delmonte, K.H. Lee, M.R. Garcia Campelo, C. Gridelli, A. Spira, R. Califano, F. Griesinger, S. Ghosh, E. Felip, D-W. Kim, P. Zhang, S. Popat, D.R. Camidge
Journal: Annals of Oncology (2020)
1441P Outcomes of neoadjuvant chemoradiation (nCRT) +/- surgery and definitive CRT (dCRT) in a single institution using the CROSS trial regimen in esophageal (EC) and gastroesophageal junction cancer (GEJC) in Canada
Authors: S. Khalid, W. Hopman, K. Virik
Journal: Annals of Oncology (2020)
1268P JASPER: Efficacy and safety of first-line (1L) niraparib plus a programmed death receptor 1 inhibitor (PD-1i) in patients with advanced non-small cell lung cancer (NSCLC)
Authors: S.S. Ramalingam, E. Thara, S. Rao, M.M. Awad, A. Dowlati, B. Haque, A.L. Veatch, T. Stinchcombe, G.K. Dy, D.R. Spigel, N. Iyer Singh, L. Evilevitch, Z. Wang, Y. Tang, I. Teslenko, M. Roychoudhury
Journal: Annals of Oncology (2020)
Cell cycle regulatory roles of ER-alpha in breast cancer
Authors: Sonia Javan Moghaddam, Khandan Keyomarsi
Journal: Cancer Research (2005)

1273  The roles of estrogen and estrogen receptor (ER) in normal mammary gland development and in transformation to a tumor phenotype have been extensively studied. However, although the cumulative data suggests an important role for ER in breast cancer, the function of ER in regulating cell proliferation in normal and tumor tissue remains unclear. This study investigates the role of ER-alpha on the progression of the cells through phases of the cell cycle in the presence and absence of the ligand (i.e. estradiol). Experimental Design: The ER negative MDA-MB 231 and ER positive MCF-7 cell lines were used for study. Cells were synchronized with lovastatin for 36 hours in estrogen free media and subsequently released from arrest with mevalonate. Transient transfection of MDA MB 231 cells with ER-alpha as well as addition of 17-b estradiol to the cells were done at the time of release from cell cycle arrest. Cells were harvested at different time points (0-68 hrs) after the release and processed for western blot and flow cytometry analysis. Results: In MCF-7 cells, the endogenous ER is subject to cell cycle regulation with its levels peaking at the S/G2 phase of the cell cycle. Similarly, MDA-MB231 cells transiently transfected with ER-alpha demonstrate tight cell cycle periodicity similar to that seen with cyclin B. Specifically, ER-alpha is up-regulated during late S phase and early G2 phase, and is down regulated during late G2 and M phase. In contrast, in non-synchronized MDA-MB 231 cells, exogenously transfected, ER levels first appear within only 12 hours of transfection, and its expression persists for several days. Additionally when 17-b estradiol is added to synchronized populations of MCF-7 cells (endogenous ER expression) or MDA-MB231 cells (exogenous ER expression), there is a shortening of the G2/M phase of the cell cycle. Our results collectively show that unliganded ER inhibits cell cycle progression during G2 and M phase in breast cancer cells, which may explain the growth inhibitory role of ER reported in the literature while liganded ER speed up the exit from G2/M phase of the cell cycle Conclusion: We conclude that the ER-alpha expression under non-liganded and liganded conditions have opposing effects on the progression of the cell cycle in G2/M phase.
669P Body composition and clinical outcomes in men with metastatic castration-resistant prostate cancer (mCRPC)
Authors: A.W. Hahn, R.S. Tidwell, D.S. Surasi, P. Msaouel, E. Efstathiou, A.J. Zurita-Saavedra, S-M. Tu, J.L. McQuade, D. Fogelman, M.W. Starbuck, S.K. Subudhi, P. Corn, P.G. Pilie, A. Aparicio, C. Logothetis
Journal: Annals of Oncology (2020)
696O_PR Nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER trial
Authors: T.K. Choueiri, T. Powles, M. Burotto, M.T. Bourlon, B. Zurawski, V.M. Oyervides Juárez, J.J. Hsieh, U. Basso, A.Y. Shah, C. Suarez, A. Hamzaj, C.H. Barrios, M. Richardet, D. Pook, Y. Tomita, B. Escudier, J. Zhang, B. Simsek, A.B. Apolo, R.J. Motzer
Journal: Annals of Oncology (2020)
1932MO Ki67 expression and CDK4/6i activity: An emerging role for PIK3CA mutations in metastatic breast cancer patients
Authors: M. Del Re, G. Lorenzini, F. Cucchiara, C. De Angelis, S. Crucitta, L. Diodati, D. Cavallero, I. Bargagna, P. Cinacchi, B. Fratini, B. Salvadori, A. Fontana, R. Danesi
Journal: Annals of Oncology (2020)
1748P Real-world outcomes in thoracic cancer patients (pts) with severe acute respiratory syndrome coronavirus 2 (COVID-19): Single UK institution experience
Authors: W. Cui, N. Yousaf, J. Bhosle, A.R. Minchom, M. Ahmed, F. McDonald, I. Locke, R. Lee, M. O'Brien, S. Popat
Journal: Annals of Oncology (2020)
1919P Nintedanib (BIBF1120) after first line therapy in progressive medullary thyroid cancer: A multicenter EORTC prospective randomized double-blind phase II study (NCT01788982)
Authors: K. Newbold, P. Schoeffski, B. Hasan, L.D. Locati, Y. Godbert, C. de la Fouchardiere, L. Bastholt, M. Fassnacht, N. Reed, Y. Lalami, C. Chougnet, C. Schvartz, E. Kapiteijn, M.J. Schlumberger, W. Sents, N. Sauve, S. Leboulleux
Journal: Annals of Oncology (2020)
53P Toripalimab with chemotherapy as first-line treatment for advanced biliary tract tumors: A preliminary analysis of safety and efficacy of an open-label phase II clinical study
Authors: T. Liu, W. Li, Y. Yu, X. Guo, X. Xu, Y. Wang, Q. Li, Y. Wang, Y. Cui, H. Liu, S. Zhang, F. Wang, M. Yao, L. Zhang
Journal: Annals of Oncology (2020)
1913O Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET+ MTC)
Authors: M. Hu, V. Subbiah, L.J. Wirth, M. Schuler, A.S. Mansfield, M.S. Brose, G. Curigliano, S. Leboulleux, V.W. Zhu, B. Keam, I. Matos, C-C. Lin, D. Adkins, C.S. Baik, G. Lopes, Y. Godbert, D. Sarker, H. Zhang, C. Turner, M. Taylor
Journal: Annals of Oncology (2020)

Pralsetinib is a highly potent, selective RET inhibitor targeting oncogenic RET alterations. We provide the registrational data for pts with RET+ MTC from the ARROW study. ARROW (75 sites in 11 countries; NCT03037385) consists of a phase I dose escalation to establish the recommended phase II dose (400 mg once daily [QD] orally), and phase II expansion cohorts defined by tumour type and/or RET alteration. Primary phase II objectives are overall response rate (ORR; blinded independent central review per RECIST v1.1) and safety. We report efficacy for response-evaluable pts (REP) with RET+ MTC and safety for all pts who initiated pralsetinib 400 mg QD, both as of data cut-off date 13 Feb 2020. In 79 REP with RET+ MTC (mutation: 61% M918T, 28% C634X, 4% V804X, 8% other), ORR was 65% (95% CI, 53–75; n=51/79, 5% complete response [CR]; 59% partial response [PR; 1 pending confirmation]). ORR for pts with prior cabozantinib and/or vandetanib (C/V) was 60% (95% CI, 46–74; n=32/53; 2% CR; 58% PR [1 pending]) and in treatment-naïve pts ORR was 74% (95% CI, 49–91; n=14/19; 5% CR; 68% PR; all confirmed). Disease control rate was 97% (95% CI, 91–100); 99% (78/79) of pts experienced tumour shrinkage. Median progression-free survival (PFS) and duration of response (DOR) were not reached. In pts previously treated with C/V 18-mo PFS was 71% (95% CI, 58–85), and 18-mo DOR was 90% (95% CI, 77–100). In treatment-naïve pts, 18-mo PFS was 85% (95% CI, 65–100) and 86% (12/14) of responses were ongoing at data cut-off (up to 15 mo). Responses occurred regardless of RET genotypes (somatic or germline), including 5 of 6 pts with V804X gatekeeper mutation. In the safety population (n=438), treatment-related adverse events (TRAEs) were primarily grade 1–2; most common any-grade TRAEs were increased aspartate aminotransferase (34%), anaemia (24%), increased alanine aminotransferase (23%), constipation (23%) and hypertension (22%). 4% of pts discontinued due to TRAEs. Pralsetinib demonstrated potent and durable clinical activity in RET+ MTC regardless of prior treatment with approved multikinase inhibitors or RET-mutation and was well tolerated.
369MO Final results of depatuxizumab mafodotin plus temozolomide in recurrent glioblastoma patients: Real-world experience from a multicenter study of Italian Association of Neuro-Oncology (AINO)
Authors: M. Padovan, M. Eoli, A. Pellerino, S. Rizzato, C. Caserta, M. Simonelli, M. Michiara, M. Caccese, E. Anghileri, G. Finocchiaro, V. Zagonel, R. Rudà, G. Lombardi
Journal: Annals of Oncology (2020)
Single-Cell RNA Sequencing Analysis Reveals a Crucial Role for CTHRC1 (Collagen Triple Helix Repeat Containing 1) Cardiac Fibroblasts After Myocardial Infarction
Authors: Adrián Ruiz-Villalba, Juan P. Romero, Silvia C. Hernández, Amaia Vilas-Zornoza, Nikolaus Fortelny, Laura Castro-Labrador, Patxi San Martin-Uriz, Erika Lorenzo-Vivas, Paula García-Olloqui, Marcel Palacio, Juan José Gavira, Gorka Bastarrika, Stefan Janssens, Ming Wu, Elena Iglesias, Gloria Abizanda, Xabier Martinez de Morentin, Miren Lasaga, Nuria Planell, Christoph Bock, Diego Alignani, Gema Medal, Igor Prudovsky, Yong-Ri Jin, Sergey Ryzhov, Haifeng Yin, Beatriz Pelacho, David Gomez-Cabrero, Volkhard Lindner, David Lara-Astiaso, Felipe Prósper
Journal: Circulation (2020)

Background: Cardiac fibroblasts (CFs) have a central role in the ventricular remodeling process associated with different types of fibrosis. Recent studies have shown that fibroblasts do not respond homogeneously to heart injury. Because of the limited set of bona fide fibroblast markers, a proper characterization of fibroblast population heterogeneity in response to cardiac damage is lacking. The purpose of this study was to define CF heterogeneity during ventricular remodeling and the underlying mechanisms that regulate CF function. Methods: Collagen1α1–GFP (green fluorescent protein)–positive CFs were characterized after myocardial infarction (MI) by single-cell and bulk RNA sequencing, assay for transposase-accessible chromatin sequencing, and functional assays. Swine and patient samples were studied using bulk RNA sequencing. Results: We identified and characterized a unique CF subpopulation that emerges after MI in mice. These activated fibroblasts exhibit a clear profibrotic signature, express high levels of Cthrc1 (collagen triple helix repeat containing 1), and localize into the scar. Noncanonical transforming growth factor–β signaling and different transcription factors including SOX9 are important regulators mediating their response to cardiac injury. Absence of CTHRC1 results in pronounced lethality attributable to ventricular rupture. A population of CFs with a similar transcriptome was identified in a swine model of MI and in heart tissue from patients with MI and dilated cardiomyopathy. Conclusions: We report CF heterogeneity and their dynamics during the course of MI and redefine the CFs that respond to cardiac injury and participate in myocardial remodeling. Our study identifies CTHRC1 as a novel regulator of the healing scar process and a target for future translational studies.
1400P Vibostolimab, an anti-TIGIT antibody, as monotherapy and in combination with pembrolizumab in anti-PD-1/PD-L1-refractory NSCLC
Authors: M-J. Ahn, J. Niu, D-W. Kim, D. Rasco, K.F. Mileham, H.C. Chung, U.N. Vaishampayan, C. Maurice-Dror, P. Lo Russo, T. Golan, E. Chartash, D. Chen, J. Healy, M. Rajasagi, D.H. Lee
Journal: Annals of Oncology (2020)
1905P BAP1 and miR-31 combination predicts outcome in epithelioid malignant pleural mesothelioma
Authors: F. Pecci, L. Cantini, V. Cognigni, A. Murrone, F. Monaco, C. Rubini, F. Barbisan, C. Copparoni, S. Rinaldi, I. Fiordoliva, M. Di Pietro Paolo, M. Scarpelli, M. Tomasetti, L. Santarelli, R. Berardi
Journal: Annals of Oncology (2020)
159O Prognostic value of tumour infiltrating lymphocytes in young triple negative breast cancer patients who did not receive adjuvant systemic treatment; by the PARADIGM study group
Authors: V.M.T. De Jong, Y. Wang, M. Opdam, N. ter Hoeve, K. Jóźwiak, M. Hauptmann, N. Stathonikos, H. Horlings, A. Broeks, S. Michiels, E. van der Wall, P. van Diest, S. Siesling, M.K. Schmidt, S. Loi, M. Kok, S. Linn, R.F. Salgado, G. Dackus
Journal: Annals of Oncology (2020)
672P Fracture risk in men with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra 223)
Authors: A. Hijab, N. Tunariu, H. Tovey, R. Alonzi, A. Tree, J. Staffurth, M. Blackledge, A.R. Padhani, H. Stidwill, J. Finch, P. Chatfield, S. Perry, D-M. Koh, E. Hall, C. Parker
Journal: Annals of Oncology (2020)
1498TiP A multi-center, randomized, open-label, phase III study of sintilimab + ramucirumab as 1st-line treatment for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (ORIENT-106)
Authors: R. Xu, Z. Li, Z. Ma, Y. Liu, Y. Wang, H. Zhou, L. Yang, H. Li
Journal: Annals of Oncology (2020)
1634P The efficacy of continuous circulatory hyperthermic intraperitoneal chemotherapy (C-HIPEC) following cytoreductive surgery for metastatic gastrointestinal stromal tumors (GISTs)
Authors: Z. Xinhua, S. Weikun, W. Hui, C. Sile, P. Jianjun, X. Jianbo, Y. Jinning, S. Kaiyu, Y. Zhijun, C. Shirong, Z. Wenhua, H. Yulong
Journal: Annals of Oncology (2020)
743P Activity of systemic therapies after cabozantinib (CABO) in patients (pts) with metastatic renal cell carcinoma (mRCC)
Authors: L. Cerbone, V. Di Nunno, L. Carril, A. Benchimol-Zouari, R. Flippot, C. Alves Costa Silva, E. Colomba-Blameble, A. Guida, L. Derosa, B. Escudier, L. Albiges
Journal: Annals of Oncology (2020)
1763P Daily chemotherapy and treatment unit in the COVID-19 era: Lessons of the first 60 days
Authors: B.Y. Aktas, D.C. Guven, R.F. Degirmenciler, H. Taban, O.H. Aktepe, N. Kertmen, S. Kilickap, O. Dizdar, S. Aksoy, M. Erman, Ş. Yalçın, A. Turker, Z. Arik
Journal: Annals of Oncology (2020)
1685P Is cancer what determines COVID-19 oncological patient’s outcome or are other external factors involved? Experience in a hospital in Madrid, Spain
Authors: J. Rogado, B. Obispo, C. Pangua, G. Serrano-Montero, A. Martin Marino, A. Lopez-Alfonso, M. Perez-Perez, M. Fontan-Vela, M.A. Lara
Journal: Annals of Oncology (2020)
1502TiP Paclitaxel + ramucirumab versus paclitaxel alone in patients with squamous-cell carcinoma of the esophagus, refractory or intolerant to combination therapy with fluoropyrimidine and platinum-based drugs - RAMOS, a randomized phase II trial of the German Gastric Group of the AIO
Authors: S. Lorenzen, C. Pauligk, T.O. Götze, C. Michael, R.J.C. Mahlberg, H. Schmalenberg, A. Biederstädt, G. Frost, S. Heidel, A. Treschl, S. Junge, R.D. Hofheinz, M. Moehler, S-E. Al-Batran
Journal: Annals of Oncology (2020)